From: Testing chemotherapy efficacy in HER2 negative breast cancer using patient-derived spheroids
Cell line | 5-FU | Crbp | Doc | Pac | EC | EC-Doc | EC-Pac | DocAC | FEC | FEC-Doc |
---|---|---|---|---|---|---|---|---|---|---|
HCC1937 | 37.09 ± 1.92 | 80.95 ± 0.67 | 101.38 ± 2.69 | 93.37 ± 1.71 | 85.12 ± 5.26 | 87.57 ± 5.03 | 83.74 ± 10.44 | 75.06 ± 2.80 | 25.99 ± 4.12 | 22.56 ± 2.24 |
HCC1143 | 116.84 ± 13.72 | 104.71 ± 26.68 | 121.36 ± 45.60 | 81.97 ± 42.22 | 86.07 ± 24.99 | 117.00 ± 23.75 | 91.59 ± 33.35 | 97.56 ± 6.57 | 105.97 ± 20.15 | 115.57 ± 31.20 |
MCF7 | 63.77 ± 4.73 | 91.71 ± 13.55 | 81.80 ± 11.41 | 70.38 ± 5.01 | 90.96 ± 18.68 | 86.60 ± 15.68 | 59.78 ± 23.96 | 74.90 ± 16.61 | 68.40 ± 10.85 | 56.89 ± 13.37 |
T-47D | 66.29 ± 2.38 | nd | 78.13 ± 7.33 | 75.83 ± 7.83 | 81.83 ± 7.13 | 70.33 ± | 47.77 ± 8.98 | 49.88 ± 4.63 | 50.99 ± 10.40 | nd |
Mean | 78.68 | 95.09 | 99.08 | 79.77 | 86.35 | 94.26 | 74.37 | 78.62 | 71.18 | 70.06 |